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Abstract
Glioblastoma is a highly malignant tumor that easily acquires resistance to treatment. The stem-cell-like character
(stemness) has been thought to be closely associated with the treatment resistance of glioblastoma cells. In this study,
we determined that farnesyl diphosphate synthase (FDPS), a key enzyme in isoprenoid biosynthesis, plays an
important role in maintaining glioblastoma stemness. A comparison of the mRNA expression in patient-derived
glioblastoma sphere cells, which maintain stemness, and their differentiated counterparts, which lose stemness, via
RNA sequencing showed that most of the altered genes were networked in the cholesterol biosynthesis pathway. We
screened Federal Drug Administration (FDA)-approved drugs targeting speciﬁc enzymes in the cholesterol
biosynthesis pathway for their ability to inhibit glioblastoma sphere formation. Inhibitors of FDPS, such as alendronate
and zoledronate, signiﬁcantly reduced the formation of glioblastoma spheres, and alendronate was effective at a lower
molar concentration than zoledronate. Knockdown of FDPS using short hairpin RNA also completely inhibited the
formation of secondary spheres. FDPS mRNA in patients with glioblastoma was associated with malignancy in three
independent microarray data sets. RNA sequencing showed that alendronate treatment reduced the embryonic stem
cell signature and activated development- and necrosis-related pathways in glioblastoma spheres. These results
suggest that FDPS is important for the maintenance of glioblastoma stemness and that alendronate, a drug widely
used to treat osteoporosis, can be repositioned to treat glioblastoma.
Introduction
Glioblastoma, which is the most common primary
malignant brain tumor, had a low relative survival esti-
mate of 5.5% at 5 years post-diagnosis in the United States
in 2009–20131. Glioblastoma is generally treated by sur-
gery and a combination of radio- and chemotherapy. The
current ﬁrst-line chemotherapeutic drug for glioblastoma
is temozolomide, which improves the median survival of
patients by 2.5 months compared with radiotherapy
alone2,3. The majority of the molecular targeted therapy
trials for glioblastoma have not resulted in advances in
survival4; thus, there is an urgent need to ﬁnd novel
candidates to treat glioblastoma.
Stem-cell-like properties (or stemness) has been con-
sidered one of the main reasons glioblastoma is refractory
to treatment5–7. A small number of cancer cells within a
heterogeneous cancer cell population exhibit stemness
and can survive after therapeutic treatment8,9. Glio-
blastoma cells with stemness have an enhanced ability to
repair damaged DNA and are more resistant to temozo-
lomide compared with glioblastoma cells without stem-
ness10. Thus, controlling stemness is important for
effective treatment of patients with glioblastoma.
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Cancer cells with stemness have a metabolism distinct
from that of nearby non-stem cells in various cancers,
including lung, ovarian, breast, and colon cancer11–15.
Glioblastoma cells with stemness have altered oxygen
consumption and lactate production compared with cells
without stemness16; however, many issues remain unre-
solved. In this study, we found that the cholesterol
biosynthetic-related pathways were speciﬁcally upregu-
lated in patient-derived glioblastoma sphere cells, which
were enriched in stemness, compared with their differ-
entiated counterparts. In particular, farnesyl diphosphate
synthase (FDPS), a key enzyme in isoprenoid biosynthesis,
was found to play an important role in maintenance of
glioblastoma stemness.
FDPS catalyzes the conversion of isopentenyl pyr-
ophosphate and dimethylallyl pyrophosphate to geranyl
pyrophosphate and farnesyl pyrophosphate, which are
protein prenylation substrates. Because prenylation is
important for many oncogenic proteins to exert their
activity, prenylation inhibitors have been actively tested in
clinical trials to treat various cancers17,18. FDPS has been
implicated in glioblastoma drug resistance19, and the
FDPS inhibitor zoledronate20 is used to treat bone
metastasis21,22. These reports suggest that FDPS might be
a potential target for cancer treatment. In this study, we
found that FDPS was important for maintaining glio-
blastoma stemness. Moreover, the FDPS inhibitor alen-
dronate23 signiﬁcantly suppressed formation of
glioblastoma spheres. Because alendronate has been
approved by the Food and Drug Administration (FDA)
and is widely used to treat osteoporosis24,25, our results
suggest that alendronate could be repositioned to treat
glioblastoma.
Materials and methods
Cell culture and chemicals
Patient-derived TS13-18 and TS13-20 cells were
directly established from fresh male WHO grade 4 glio-
blastoma patient tissues in accordance with a protocol
approved by the Institutional Review Board of Severance
Hospital, Yonsei University College of Medicine (4-2012-
0212).
We followed previously published methods to isolate
tumor spheres (TSs) from the human brain26. These cells
were cultured as TSs in DMEM/F-12 medium (#10-0900
cv, HyClone, Logan, UT, USA) supplemented with
1 × B27 (#17504-044, Invitrogen, San Diego, CA, USA),
20 ng/ml basic ﬁbroblast growth factor (#E0291; Sigma-
Aldrich, St. Louis, MO, USA), 20 ng/ml epidermal growth
factor (#E9644, Sigma-Aldrich), and 1% penicillin-
streptomycin (#15140-122, Invitrogen) at 37 °C in a 5%
CO2 humidiﬁed incubator. The differentiated counter-
parts were cultured under the same conditions but sup-
plemented with 10% heat-inactivated fetal bovine serum
(FBS; #SH30084.03; HyClone). 293FT cells were main-
tained in DMEM supplemented with 1% penicillin-
streptomycin (#15140-122; Invitrogen), Cellmaxin
(#C3319-020; GenDEPOT, Austin, TX, USA), and 10%
heat-inactivated FBS.
Lovastatin (mevinolin; #M2147), squalestatin 1 (zar-
agozic acid A; #Z2626), alendronate (alendronate sodium
trihydrate; #A4978), zoledronate (zoledronic acid mono-
hydrate; #SML0223), and staurosporine (#S5921) were
purchased from Sigma-Aldrich. Hydrogen peroxide
(#H1222) was obtained from Tokyo chemical industry.
RNA sequencing
Total RNA from TS13-20 sphere cells was extracted
with Trizol (#15596018, Life Technologies, Carlsbad, CA,
USA) per the manufacturer’s instructions. Preparation of
an RNA library and sequencing were performed by LAS
(Seoul, Korea) in the case of TSs and their differentiated
counterparts and by Macrogen (Seoul, Korea) in the case
of alendronate-treated and non-treated TSs. Sequencing
was performed using the Next sequencing 500 system and
the HiSeq 2500 sequencing system (Illumina, San Diego,
CA, USA).
Analysis of RNA sequencing data
Gene set enrichment analysis was carried out with
GSEA version 2.2.2. A p-value was determined for the
mean rank of each gene set. Neural stem cell gene set data
were obtained from Harmonizome (http://amp.pharm.
mssm.edu/Harmonizome/)27. Embryonic stem cell gene
set data were obtained from the GSEA Molecular sig-
nature database v6.0 (http://software.broadinstitute.org/
gsea/index.jsp) by combining two gene sets:
HATTACHARYZ_
EMBRYONIC_STEM_CELL and WONG_EM-
BRYONIC_STEM_CELL_CORE. The genes in each gene
set are listed in Supplementary Table S1.
Functional enrichment analysis for biological pathway
was carried out with FunRich version 2 (http://www.
funrich.org)28. Functionally grouped Gene Ontology (GO)
terms analysis was visualized by use of ClueGO v.2.3.3 run
through Cytoscape v.3.5.129 based on Kyoto Encyclopedia
of Genes and Genomes (KEGG) (http://apps.cytoscape.
org/apps/cluego).
RNA sequencing data from alendronate-treated and
non-treated cells were analyzed via core analysis using
Ingenuity Pathways Analysis (IPA; Ingenuity Systems,
www.ingenutiy.com). Functional analysis determined the
biological functions that were most signiﬁcant to the data
set (P < 0.05).
RT-PCR and Real-time qPCR
Preparation of RNA, reverse-transcription polymerase
chain reaction (RT-PCR), and real-time quantitative PCR
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(real-time qPCR) were performed according to a modiﬁed
version of a method described previously30. Brieﬂy, total
RNA was extracted with Trizol (#15596018, Life Tech-
nologies), and cDNA was synthesized using AMV Reverse
Transcriptase (#2620 A, Takara Bio, Shiga, Japan). Real-
time qPCR was performed with a FastStart Essential DNA
Green Master Kit (#06402712001, Roche Diagnostics,
Indianapolis, IN, USA) using a Real-time PCR Light-
Cycler96 (Roche Diagnostics). The primers used are listed
below.
Gene Forward (5′– 3′) Reverse (5′– 3′)
ACTB CAAGATCATTGCTCCTCCTG GAAAGGGTGTAACGCAACTA
HMGCR TCGGTGGCCTCTAGTGAGAT TCACTGCTCAAAACATCCTCTTC
HMGCS1 CCTGGTAGTTGCAGGAGATATTG ACAGAATAGCAGCGGTCTAATG
FDPS GTGCTGACTGAGGATGAGATG GCTCGATCAGGTTCAGGTAATAG
FDFT1 GAGAAGGATCGCCAGGTGCT AGCCCAGCAACATAGTGGCA
HES6 ATTGCCCGGAGTGTCTGGAG GAGGGAGGGAAGACCTGGGA
DLL3 GTCCGAGCTCGTCCGTA GGACAGAATCGAGGAAGGGT
FUT9 TCCAGATTCACTGCTCTCCC ATTCTAAATCGGTCCTAGGGGT
GFAP TTGCAGACCTGACAGACGCT GCCTCTCCAGGGACTCGTTC
Imaging of sphere cells
Images of sphere cells were obtained using a Cyation-3
cell imaging multimode microplate reader with a ×4
objective (Bio-Tek, Winooski, VT, USA). Images were
analyzed using the ImageJ program. Colonies >10 μm in
diameter were considered sphere cells.
Limiting Dilution Assay
Limiting dilution assays were performed according to a
modiﬁed version of a method described previously31. Cells
were cultured in TS conditions with the indicated con-
centration of alendronate for 7 days.
Western blotting
Western blotting was performed according to a mod-
iﬁed version of a method described previously32. Cells
were lysed with lysis buffer containing 20mM Tris-Cl (pH
7.4), 150mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100,
and protease inhibitors (#p3100-010, GenDEPOT). Anti-
β-actin antibody (#A2228) was purchased from Sigma,
and anti-FDPS antibody (#ab153805) was obtained from
Abcam (Cambridge, MA, USA). Images were obtained
using a Fusion SL/SOLO imaging system (Vilber Lour-
mat, France).
Confocal microscopy
Confocal microscopy was performed according to a
modiﬁed version of a method described previously33.
Tumor sphere cells were seeded in a Lab Tek II 8-
chamber (#155409; Thermo Scientiﬁc, Waltham, MA,
USA) coated with Cell Tak (#354240; Corning, Corning,
NY, USA). The sphere cells were ﬁxed in 4% paraf-
ormaldehyde, permeabilized with 0.5% Triton X-100, and
stained with anti-FDPS antibody (#ab153805; Abcam) and
Alexa Fluor 488-conjugated anti-rabbit antibody
(#A11008; Thermo Scientiﬁc). Nuclei were stained with
DAPI (#268298; Calbiochem, San Diego, CA, USA).
Images were obtained at ×20 at the Imaging Core
(National Cancer Center) on a LSM510 META or
LSM780 confocal microscope (Carl Zeiss, Jena, Germany).
For determination of the type of cell death, TS cells were
treated with various death-inducing reagents, stained with
Hoechst (#H3570, Thermo, 10 μg/ml) and propidium
iodide (#LS-02-100, Biobud, 0.3 μg/ml) and then imaged
with the LSM780 confocal microscope. Z-stack orthogo-
nal projection images were processed with ZEN 2012
analysis software (Carl Zeiss, Germany).
Lentiviral short hairpin RNA (shRNA)-mediated FDPS
knockdown
Human FDPS targeting sequences were designed using
the Broad Institute GPP web portal (http://www.
broadinstitute.org/
rnai/public/gene/search). Target sequences were syn-
thesized by Macrogen (Seoul, Korea), annealed, and
inserted into the EcoRI and AgeI sites of a pLKO.1 puro
vector (Plasmid #8453, Addgene, Cambridge, MA, USA).
As controls, sh-scrambled (Plasmid #1864, Addgene) or
empty vector were used.
Target sequence (5′– 3′)
sh-FDPS #1 CCAGCAGTGTTCTTGCAATAT
sh-FDPS #2 CCCAGAGATAGGAGATGCTAT
sh-scrambled CCTAAGGTTAAGTCGCCCTCG
Lentivirus was produced according to a modiﬁed ver-
sion of a method described previously34. Experiments
were carried out in accordance with the National Cancer
Center, Institutional Biosafety Committee-approved pro-
tocol (17-NCCIBC-008). Brieﬂy, 293FT cells were co-
transfected with shRNA vectors and the packaging vectors
psPAX2 (plasmid #12260; Addgene) and pMD2.G (plas-
mid #12259, Addgene) using polyethylenimine (#24313;
Polysciences, Inc., Warrington, PA, USA). Two days after
transfection, the culture media were ﬁltered using a
Minisart Syringe Filter (0.45 μm, #16555; Sartorius,
Bohemia, NY, USA), and the lentivirus was concentrated
using plus PEG-it Virus precipitation solution 5×
(#LV810A-1, SBI).
Glioblastoma TS cells were infected with lentiviral
shRNAs in the presence of 0.8 μg/ml polybrene (#H9268;
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Sigma) for 6 h, and the media were exchanged with fresh
complete media. Two days after the infection, the infected
cells were selected with 1 μg/ml puromycin (#AMR-J593;
Amresco, Solon, OH, USA) for 2 additional days. Selected
glioblastoma TS cells were seeded in 96-well clear ﬂat-
bottom, ultralow attachment microplates (#3474; Corn-
ing) and maintained for 4 days, and then images were
obtained. The same number of cells were reseeded in 96-
well microplates for secondary sphere culture and main-
tained for 6 days.
Statistics
Statistical analysis was performed as previously repor-
ted12. The data are presented as the means ± standard
deviation, and P values were calculated using a Student’s t
test calculator. All the data are representative of at least
three separate experiments.
Results
Patient-derived glioblastoma sphere cells are enriched in
the stem cell signature
First, we optimized the conditions to differentiate
patient-derived glioblastoma sphere cells, which have
been reported to harbor stemness26,35,36. Morphological
differentiation was induced by adding 10% fetal bovine
serum for 7 days to tumor sphere (TS) cultures of two
independent patient-derived glioblastoma sphere cell sets,
called TS13-20 and TS13-18 (Fig. 1a, b). Previously, we
determined that glioblastoma patient-derived TS cells
formed diffuse tumors that resembled that of the patient
in a mouse orthotopic model and differentiated into
astrocytes, oligodendrocytes, and the neuronal lineage26.
We determined whether our TS cells harbored similarities
to stem cells at the global mRNA level. Total RNA was
isolated from TS13-20 sphere cells (marked D0) and their
differentiated counterparts (marked D7, which were
treated with 10% serum for 7 days) and analyzed via RNA
sequencing. Gene set enrichment analysis (GSEA) showed
that the TS cells were enriched in embryonic stem cell
and neural stem cell signatures compared with their dif-
ferentiated counterparts (Fig. 1c, Supplementary
Table S1). The RNA-sequencing results were validated by
RT-PCR for some of the genes (Fig. 1d). These results
suggest that patient-derived glioblastoma sphere cells
were enriched in the stem cell signature and lost their
stemness after serum-induced differentiation.
Cholesterol pathway genes are the most differentially
expressed between sphere and differentiated cells
We identiﬁed differentially expressed genes (DEGs)
between TS13-20 sphere (D0) cells and their differ-
entiated counterparts (D7). In total, 493 genes were
upregulated and 375 genes were downregulated in D7
cells, which was more than four-fold that in D0 cells
(Fig. 2a and Supplementary Table S2). A biological
pathway analysis showed that cholesterol-related path-
ways were predominantly altered between sphere cells
and their differentiated counterparts (Fig. 2b). Upregu-
lated genes in sphere cells were categorized into steroid
biosynthesis, aldosterone synthesis and secretion, and
terpenoid backbone biosynthesis pathways, all of which
are components of cholesterol biosynthesis (Fig. 2c left).
Downregulated genes in sphere cells were categorized
into extracellular matrix-receptor interaction, protein
digestion and absorption, complement and coagulation
cascades, and arachidonic acid metabolism pathways
(Fig. 2c right). This result suggests that cholesterol bio-
synthesis was upregulated in patient-derived glioblastoma
sphere cells.
Next, we determined whether other metabolic pathways
were altered during differentiation of glioblastoma sphere
cells. Among the reported gene sets in various metabolic
pathways12, the cholesterol gene set was the only one that
changed signiﬁcantly (Fig. 2d). The most expressed genes
in D0 cells were FDFT1, FDPS, and HMGCS1 (Fig. 2e).
RT-PCR and real-time qPCR validated the RNA-
sequencing results (Fig. 2f). Moreover, TS13-18 cells
also upregulated HMGCS1, HMGCR, FDPS, and FDFT1
in sphere cells compared with their differentiated coun-
terparts (Fig. 2f). These results suggest that the cholesterol
pathway was speciﬁcally upregulated in TS cells harboring
stemness and that the cholesterol pathway might play a
role in maintaining glioblastoma stemness.
Pharmacological inhibition of FDPS suppresses formation
of glioblastoma sphere cells
To assess whether cholesterol biosynthesis is important
for maintaining glioblastoma sphere cells, we treated the
cells with pharmacological inhibitors of the core choles-
terol pathway genes (Fig. 3a) during TS culture. Alen-
dronate, zoledronate (FDA-approved FDPS
inhibitors)20,23,25 and lovastatin (FDA-approved HMGCR
inhibitor)37 apparently inhibited TS formation in patient-
derived cells (TS13-20 and TS13-18) at 5–20 μM; how-
ever, squalestatin 1 (FDFT1 inhibitor)38 did not (Fig. 3b).
Quantitative analysis of intact and damaged spheres
showed that alendronate signiﬁcantly decreased the
number of intact spheres and signiﬁcantly increased the
number of damaged spheres at 5 μM for all TS cell types
(Fig. 3c). Limiting dilution assays showed that alendronate
reduced the stem cell population of TS cells at 5 μM for
TS13-20 cells and at 10 μM for TS13-18 cells (Fig. 3d).
Moreover, damaged spheres could not form TSs even in
the absence of alendronate in the secondary TS formation
assay (Fig. 3e). Quantitative analysis of the limiting dilu-
tion assays showed that 50 cells were sufﬁcient to form
secondary TSs in all the wells in a 96-well plate for intact
TSs not treated with alendronate; however, alendronate-
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treated damaged TSs did not form secondary TSs in the
majority of the wells (Fig. 3f). The differentiated coun-
terparts of TS cells were relatively insensitive to alen-
dronate, and their growth was inhibited at 30–50 μM
(Fig. 3g). These results suggest that pharmacological
inhibition of FDPS speciﬁcally suppressed the main-
tenance of glioblastoma stem cells.
Knockdown of FDPS effectively inhibits tumor sphere
formation
We ﬁrst checked whether the FDPS mRNA level was
reﬂected by its protein level to conﬁrm the role of FDPS in
the formation of glioblastoma sphere cells. Western
blotting showed that the FDPS protein expression level
decreased signiﬁcantly in differentiated cells compared
with that in their TS counterparts (Fig. 4a). Then, we
knocked down FDPS using short hairpin RNA (shRNA)
and conﬁrmed downregulation of the FDPS protein level
via immunoﬂuorescence staining and confocal micro-
scopy (Fig. 4b). Knockdown of FDPS almost completely
inhibited the formation of secondary TSs in patient-
derived glioblastoma sphere cells (Fig. 4c), suggesting that
FDPS is critical for the maintenance of glioblastoma
sphere cells.
In accordance with these ﬁndings, FDPS mRNA was
signiﬁcantly upregulated in glioblastoma cells compared
with normal cells (Fig. 4d left and middle) and in samples
from patients who died within 3 years compared with
samples from living patients (Fig. 4d right) in three
independent microarray data sets39–41.
Alendronate reduces the embryonic stem cell signature
and activates the necrosis-related pathway
To investigate the molecular changes triggered by
alendronate treatment, we analyzed DEGs between
alendronate-treated and non-treated TS13-20 cells using
RNA sequencing. In total, 424 genes were upregulated
and 134 genes were downregulated in alendronate-treated
cells, which was more than two-fold that in non-treated
cells (Fig. 5a and Supplementary Table S3). GSEA showed
Embryonic stem cell gene set
p-value=0.000
NES=2.130
FDR=0.000
‘D0’ (positively 
correlated)
p-value=0.006
NES=1.224
FDR=0.006
‘D0’ (positively 
correlated)
Neural stem cell gene set
a b
c d
Fig. 1 Patient-derived glioblastoma sphere cells are enriched in the stem cell signature. a, b Serum-induced differentiation of patient-derived
glioblastoma sphere cells. Bright ﬁeld image of cells taken using a Cytation 3 microplate reader (Bioteck) after the addition of (a) various
concentrations of serum for 7 days and (b) 10% serum for the indicated number of days; a representative image of at least three independent
experiments is shown. c The expression level of total RNA from TS13-20 spheres (D0) and their differentiated counterparts (D7) that were treated with
10% serum for 7 days was determined by RNA sequencing. Gene set enrichment analysis (GSEA) showed that sphere cells were enriched in neural
stem cell and embryonic stem cell gene signatures. (NES: normalized enrichment score, FDR: false discovery rate). Gene sets are listed in
Supplementary Table S1. d RNA sequencing results were validated by analyzing the expression of genes using reverse-transcription polymerase chain
reaction (RT-PCR). ACTB was used as the loading control. Representative images of the 3 independent experiments are shown
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Fig. 2 (See legend on next page.)
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that embryonic but not neural stem cell signatures were
downregulated in alendronate-treated cells compared
with non-treated cells (Fig. 5b). Core analysis by Ingenuity
Pathway Analysis (IPA) showed that the most signiﬁcantly
altered canonical pathway was the complement system,
which was upregulated by alendronate treatment (Fig. 5c).
Downstream effect analysis of disease and functions
showed that various developmental processes and
necrosis were activated, whereas apoptosis was inactivated
(Fig. 5d). Visualization of necrosis-related genes clearly
showed that necrosis-promoting genes were upregulated
and necrosis-inhibiting genes were downregulated by
alendronate treatment (Fig. 5e). To validate these bioin-
formatic analysis results, we looked closely at the shape of
the nuclei upon alendronate treatment. When assessing
dead cells using propidium iodide, a membrane
impermeable intercalating dye, alendronate-treatment-
induced dead cells showed intact nuclei, which were
similar to those in cells undergoing necrotic death
induced by hydrogen peroxide treatment. Whereas cells
undergoing apoptotic death caused by staurosporine
showed fragmented nuclei42 (Fig. 5f). This result suggests
that alendronate induces glioblastoma stem cell differ-
entiation and causes cell death via the necrosis-related
pathway. Overall, our ﬁndings suggest that glioblastoma
cells rely on FDPS for the maintenance of stemness and
that alendronate is a potential candidate drug for glio-
blastoma treatment (Fig. 5g).
Discussion
Cancer cells maintain or acquire stemness by exploiting
that of normal stem cells. Normal stem cells are generally
classiﬁed as embryonic or adult stem cells. Distinct core
transcriptional networks govern embryonic and adult
stemness; embryonic stem cells rely on OCT4, SOX2, and
NANOG for maintenance of pluripotency43, whereas the
key players in adult cell stemness have not been fully
revealed. A recent report showed that the core networks
governing neural stem cells completely differ from those
governing embryonic stem cells44. Thus, it is important to
determine whether cancer exploits normal embryonic or
adult stemness characteristics. Aggressive cancer cells are
enriched in the embryonic stem cell-like gene expression
signature45, and the embryonic stem cell-like transcrip-
tional program strongly predicts metastasis and death46,
suggesting that cancer cells exploit embryonic stemness.
In contrast, two recent reports clearly show that lung
cancer cells with stemness rely on normal lung adult
stem-cell-speciﬁc signaling pathways47,48. In the present
study, the GSEA showed that glioblastoma TS cells were
enriched in both neural and embryonic stem cell genes
(Fig. 1), suggesting that cancer can exploit both embryo-
nic and adult stemness simultaneously.
We found that the cholesterol biosynthesis of glio-
blastoma cells with stemness distinctly differed from that
of those without stemness (Fig. 2). The cholesterol path-
way has been linked to glioblastoma; however, its link to
glioblastoma stem cells has not been rigorously investi-
gated. Upregulation of mevalonate and the cholesterol
synthesis pathway is associated with poor survival in
patients with glioblastoma49. HMGCR, a key cholesterol
biosynthetic enzyme, has been widely studied as a target
for glioblastoma treatment, and its inhibitors, statins, are
under various clinical trials for glioblastoma treatment,
although most trials are in the early stage (clinicaltrials.
gov). Recent studies have shown that glioblastoma
depends on cholesterol for survival and that it is sensitive
to liver X receptor agonists50 or inhibition of sterol reg-
ulatory element-binding protein-151. Considering that
normal neural stem and progenitor cells are highly active
in de novo lipid synthesis and depend on it for their
proliferation52, glioblastoma cells might exploit normal
neural stem cell metabolism for maintenance of their
stemness.
FDPS has been implicated in the paclitaxel resistance of
a glioblastoma cell line19, and Abate et al. showed that
FDPS mRNA and protein levels, as well as enzyme
activity, are upregulated in samples from patients with
glioblastoma compared with normal human astrocytes
and peripheral samples from tumor-free brains53. FDPS
mRNA levels are also upregulated in glioblastoma sam-
ples compared with normal samples in other microarray
(see ﬁgure on previous page)
Fig. 2 The most differentially expressed genes (DEGs) in sphere and differentiated cells are cholesterol pathway genes. a DEGs between
TS13-20 spheres (D0) and their differentiated counterparts (D7) were analyzed by RNA sequencing. Genes with expression changes more than four-
fold are shown. DEGs are listed in Supplementary Table S2. b The cholesterol biosynthesis-related pathway was the dominant pathway altered in
sphere (D0) cells according to functional enrichment analysis using FunRich (http://www.funrich.org). The top ﬁve pathways are presented. c Down-
and upregulated DEGs were subjected to gene network analysis using Cytoscape (http://www.cytoscape.org). Gene networks with P values < 0.005
are shown. d The change in the mRNA expression of various metabolic pathway genes between D0 and D7 cells was analyzed. Cholesterol-related
genes were the only metabolic genes that varied between the two samples. The marker size is proportional to the log2-fold change (D0/D7).
e Heatmap showing a clear distinction between the cholesterol pathway-related gene expression levels in the two samples. f Changes in the
expression of cholesterol pathway genes were validated by RT-PCR and real-time quantitative PCR. The data are presented as the means of three
independent experiments. ***P < 0.001 relative to D0
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data sets (Fig. 4d). Additionally, knockdown of FDPS
almost completely blocks secondary tumor sphere for-
mation by patient-derived glioblastoma tumor spheres
(Fig. 4c). These results suggest that FDPS is a potential
therapeutic target for glioblastoma treatment. Moreover,
zoledronate and alendronate, which are FDA-approved
FDPS inhibitors, have been widely used to treat osteo-
porosis. Zoledronate is undergoing clinical trials for
treatment of various cancers, including prostate and
breast cancer, but not glioblastoma (clinicaltrials.gov).
Zoledronate enhances the anti-tumor effect of temozo-
lomide in glioblastoma cell lines54; however, it does not
cross the blood–brain barrier (BBB)55. In this study,
alendronate inhibited the formation of glioblastoma
spheres at a lower molar concentration than that of
zoledronate (Fig. 3). Alendronate is currently not being
(see ﬁgure on previous page)
Fig. 3 Pharmacological inhibition of farnesyl diphosphate synthase (FDPS) suppresses glioblastoma sphere formation. a Abbreviated
representation of cholesterol synthesis. Black, metabolite; red, key enzymes; blue, FDA-approved drugs that inhibit the indicated enzymes.
b, c Alendronate inhibited glioblastoma sphere formation. Patient-derived glioblastoma sphere cells (TS13-20 and TS13-18) were treated with the
indicated concentrations of drugs for 7 days. Bright ﬁeld images of cells were taken with a Cytation 3 microplate reader (Bio-Tek, Winooski, VT, USA).
b A representative image of the experiment is shown. c Intact and damaged spheres were quantiﬁed (n= 3). ***P < 0.001, **P < 0.01, *P < 0.05, and
NS P > 0.05 relative to the number of spheres cultured under no-drug-treatment conditions. d Limiting dilution assays were performed in TS13-20
and TS13-18 cells treated with the indicated concentration of alendronate. e Damaged spheres did not form secondary spheres. TSs cultured for
7 days were treated with or without alendronate for 7 days. Then, all sphere cells (intact and damaged) were subjected to secondary sphere
formation. Bright ﬁeld images of cells were taken 7 days after secondary culture using Cytation 3; a representative image of at least three
independent experiments is shown. f Limiting dilution assays were performed with intact and damaged sphere cells under the same conditions
described in (e). g Alendronate was less effective in differentiated cells than in sphere cells. Glioblastoma sphere cells (TS13-20, TS13-18) were
differentiated for at least 7 days. Differentiated cells (Diff13-20, Diff13-18) were treated with the indicated concentration of alendronate for 7 days.
Bright ﬁeld images were obtained using a JuLI Br system (NanoEnTek, Inc., Korea); a representative image of at least three independent experiments is
shown
Fig. 4 Knockdown of farnesyl diphosphate synthase (FDPS) suppresses glioblastoma sphere formation. a The protein levels of FDPS between
TS13-20 and TS13-18 cell spheres (D0) and differentiated counterparts (D7) were analyzed by western blot. ACTB was used as the loading control.
b TS13-20 cells were infected with lentivirus harboring short hairpin RNAs (shRNAs) against FDPS. Two days after infection, the infected cells were
selected for 2 days and then maintained an additional 4 days. Knockdown of the FDPS protein was assessed by immunoﬂuorescence staining and
confocal microscopy. Images were obtained at ×20 using an LSM510 META or LSM780 confocal microscope (Carl Zeiss, Jena, Germany). c Knockdown
of FDPS inhibited secondary sphere formation. The same number of control and FDPS knockdown cells were subjected to secondary sphere
formation. Bright ﬁeld images were obtained using a Cytation 3 microplate reader (Bio-Tek). d FDPS gene expression was signiﬁcantly upregulated in
glioblastoma cells compared with normal cells and in samples with a dead status at 3 years compared with samples with a live status. Three
independent microarray-based data sets were median centered and normalized to the unit standard deviation to compare the gene expression level
according to the P-value
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Embryonic stem cell gene set
p-value=0.000
NES=4.442
FDR=0.000
Neural Stem cell gene set
p-value=0.175
NES=1.176
FDR=0.175
‘0μM’ (positively 
correlated)
a
d e
f g
b c
Fig. 5 Alendronate reduces the embryonic stem cell signature and activates necrosis in glioblastoma spheres. a DEGs between TS13-20 cells
treated with or without alendronate (10 μM) for 7 days were analyzed by RNA sequencing. Genes with expression changes greater than two-fold are
shown. DEGs are listed in Supplementary Table S3. b GSEA showed that embryonic stem cell gene signatures were downregulated in alendronate-treated
cells. c, d DEGs were analyzed by core analysis using Ingenuity® Pathway Analysis (IPA). c Canonical pathway analysis showed that the most functionally
inﬂuenced mechanistic network was the complement system. d Downstream effect analysis showed that necrosis- and development-related genes were
activated by treatment with alendronate in the disease and functions category. A: cell viability of neurons, B: cell viability, C: neuronal cell death, D–F:
apoptosis, G: necrosis, H-J: cellular development, K-M: tissue development, N–O: nervous system development and function, P: embryonic development,
Q: organismal development, R: connective tissue development and function. e The network of necrosis-related DEGs induced by treatment with
alendronate is shown. f Alendronate caused necrosis-related cell death. TS13-20 cells were treated with staurosporine (0.5 μM, 18 h), hydrogen peroxide (1
mM. 18 h), or alendronate (10 μM, 3 days) and then stained with Hoechst and propidium iodide. Z-stack orthogonal projection images were obtained with
an LSM780 confocal microscope and processed using ZEN 2012 analysis software (Carl Zeiss, Germany). g A model linking FDPS with glioblastoma
stemness. Glioblastoma TS cells rely on FDPS for maintenance of stemness, and alendronate is a potential candidate drug for glioblastoma treatment
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evaluated in a clinical trial for glioblastoma treatment
(clinicaltrials.gov); however, because it can cross the
BBB56, our results suggest that it may be a good candidate
for clinical trials aimed at glioblastoma treatment.
Recently, embryonic stemness was found to be impor-
tant in the stemness index of human pan-cancer
patients57. Alendronate reduced the embryonic stem cell
signature in glioblastoma (Fig. 5b), and thus, it may also
regulate stemness in various other cancers. Alendronate
regulated not only stemness but also cell death. Although
knockdown of FDPS resulted in apoptosis in glioblastoma
cells cultured in adherent conditions53, our data suggest
that alendronate triggers necrosis-related cell death in
patient-derived glioblastoma TSs (Fig. 5d, f), reﬂecting
differences between adherent and TS cultures of primary
glioblastoma35. In addition, the complement system was
upregulated by both differentiation induction and alen-
dronate treatment in glioblastoma TSs (Figs. 2c and 5c).
The complement system has been closely linked to cancer
immunotherapy58, and thus, alendronate may be used in
combination with anti-cancer immunotherapeutic drugs.
Farnesyl pyrophosphate, generated by FDPS, can be
used to synthesize cholesterol via conversion to squalene
by FDFT1, or it can be used in prenylation, which is a
post-translational modiﬁcation (Fig. 3a). In this study,
inhibiting FDPS but not FDFT1 signiﬁcantly affected TS
formation (Fig. 3b), suggesting that protein prenylation
may be important for glioblastoma TS formation. Indeed,
abnormal protein prenylation has been attributed to the
progression of several cancer types17,18, and prenylation of
Ras and Rho has been implicated in glioma59,60. Thus, it is
likely that FDPS affects TS maintenance by regulating
protein prenylation.
Taken together, these data indicate that patient-derived
glioblastoma sphere cells rely on the cholesterol
biosynthesis-related pathway for maintenance of stem-
ness. In particular, alendronate, an FDA-approved FDPS
inhibitor, signiﬁcantly suppressed maintenance of glio-
blastoma spheres. Our results suggest that an FDA-
approved drug targeting cholesterol pathway-related
genes could be repositioned for treatment of patients
with glioblastoma.
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